Concert Pharmaceuticals Inc (NASDAQ:CNCE) Director Ronald W. Barrett sold 14,156 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $24.70, for a total value of $349,653.20. Following the transaction, the director now directly owns 3,539 shares in the company, valued at $87,413.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Concert Pharmaceuticals Inc (CNCE) traded down $0.26 during trading hours on Wednesday, reaching $23.47. The company’s stock had a trading volume of 401,800 shares, compared to its average volume of 245,935. Concert Pharmaceuticals Inc has a 52-week low of $7.11 and a 52-week high of $25.41.

A number of equities research analysts recently commented on CNCE shares. Stifel Nicolaus reissued a “buy” rating and issued a $30.00 price target on shares of Concert Pharmaceuticals in a research report on Sunday, October 22nd. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Concert Pharmaceuticals in a research report on Monday, September 18th. Zacks Investment Research lowered Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, Mizuho started coverage on Concert Pharmaceuticals in a research report on Thursday, October 26th. They issued a “buy” rating and a $23.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $23.00.

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Concert Pharmaceuticals by 11.0% in the 2nd quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock valued at $10,553,000 after purchasing an additional 74,801 shares during the period. Northern Trust Corp grew its stake in Concert Pharmaceuticals by 11.2% in the 2nd quarter. Northern Trust Corp now owns 243,989 shares of the biotechnology company’s stock valued at $3,403,000 after purchasing an additional 24,622 shares during the period. Geode Capital Management LLC grew its stake in Concert Pharmaceuticals by 0.6% in the 1st quarter. Geode Capital Management LLC now owns 142,740 shares of the biotechnology company’s stock valued at $2,435,000 after purchasing an additional 838 shares during the period. Alps Advisors Inc. grew its stake in shares of Concert Pharmaceuticals by 6.3% during the 2nd quarter. Alps Advisors Inc. now owns 20,362 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 1,200 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Concert Pharmaceuticals by 47.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 32,122 shares of the biotechnology company’s stock worth $449,000 after acquiring an additional 10,400 shares during the period. Hedge funds and other institutional investors own 65.36% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://theolympiareport.com/2017/12/06/ronald-w-barrett-sells-14156-shares-of-concert-pharmaceuticals-inc-cnce-stock.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.